ACC 2016:女性可通过钼靶筛查识别早期心血管风险

2016-03-25 Seven L MedSci原创

在芝加哥举行的第65届美国心脏病学会科学会议称,常规钼靶可识别女性的心脏病风险,进行更早期的干预。研究成果将于4月4日发表在JACC: Cardiovascular Imaging。Laurie Margolies博士和同事对292名行钼靶和CT的女性进行了一项研究,探究乳房动脉钙化(BAC)和冠状动脉钙化(CAC)的关系。研究数据显示,BAC存在于42.5%的女性中,这类女性中有70%的伴有CA

在芝加哥举行的第65届美国心脏病学会科学会议称,常规钼靶可识别女性的心脏病风险,进行更早期的干预。研究成果将于4月4日发表在JACC: Cardiovascular Imaging。

Laurie Margolies博士和同事对292名行钼靶和CT的女性进行了一项研究,探究乳房动脉钙化(BAC)和冠状动脉钙化(CAC)的关系。

研究数据显示,BAC存在于42.5%的女性中,这类女性中有70%的伴有CAC。此外60岁以下女性中有一半的有BAC,更年轻的BAC女性中有83%的伴有CAC。与先前的研究一致,BAC是心血管风险的强预测因素。

研究的共同作者、JACC: Cardiovascular Imaging的总编辑Jagat Narula博士说:“研究表明,我们现在有许多提供关于亚临床冠状动脉疾病信息的数据,本研究中,BAC对亚临床动脉粥样硬化的预测价值等同于标准的危险因素。不过数据并不来自于前瞻性研究,存在选择性偏倚。虽然我们和其他人都观察到了BAC和CAC之间的联系,但是血管的钙化机制却不同,期间的直接联系我们也不知道。不过当你发现有能预测亚临床冠状动脉疾病信息的数据,就应该提高警觉。”

另外Amorina Ishai博士和同事对293名进行PET/CT扫描后发现,大脑压力中心活动度越大,心血管事件风险越高,活动度每增加1U,风险增加14倍。超过5年的随访发现,高压和低压参与者相比,心血管事件发生率分别为35%和15%。

作者指出,以后还需要更多的研究去探究压力与心血管事件的关系,通过降低大脑压力中心的活动度,能否减少动脉粥样硬化相关炎症,进而降低心血管事件风险。

原始出处:

Study Finds Routine Mammography May be Useful For Heart Disease Screening.Mar 24, 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2082370, encodeId=a79020823e0c2, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Apr 24 12:28:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325203, encodeId=5a7f132520345, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 27 10:28:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73884, encodeId=9c0be3884cb, content=需要进一步的研究证实, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160414/IMG570FBE7A07E895161.jpg, createdBy=681a1704705, createdName=田田7760, createdTime=Sat Mar 26 18:50:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73821, encodeId=1895e3821a4, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Sat Mar 26 06:45:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73803, encodeId=4139e3803e3, content=是这样吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:35:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73804, encodeId=db91e380452, content=要多看文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:35:00 CST 2016, time=2016-03-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2082370, encodeId=a79020823e0c2, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Apr 24 12:28:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325203, encodeId=5a7f132520345, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 27 10:28:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73884, encodeId=9c0be3884cb, content=需要进一步的研究证实, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160414/IMG570FBE7A07E895161.jpg, createdBy=681a1704705, createdName=田田7760, createdTime=Sat Mar 26 18:50:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73821, encodeId=1895e3821a4, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Sat Mar 26 06:45:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73803, encodeId=4139e3803e3, content=是这样吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:35:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73804, encodeId=db91e380452, content=要多看文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:35:00 CST 2016, time=2016-03-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2082370, encodeId=a79020823e0c2, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Apr 24 12:28:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325203, encodeId=5a7f132520345, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 27 10:28:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73884, encodeId=9c0be3884cb, content=需要进一步的研究证实, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160414/IMG570FBE7A07E895161.jpg, createdBy=681a1704705, createdName=田田7760, createdTime=Sat Mar 26 18:50:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73821, encodeId=1895e3821a4, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Sat Mar 26 06:45:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73803, encodeId=4139e3803e3, content=是这样吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:35:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73804, encodeId=db91e380452, content=要多看文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:35:00 CST 2016, time=2016-03-26, status=1, ipAttribution=)]
    2016-03-26 田田7760

    需要进一步的研究证实

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2082370, encodeId=a79020823e0c2, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Apr 24 12:28:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325203, encodeId=5a7f132520345, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 27 10:28:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73884, encodeId=9c0be3884cb, content=需要进一步的研究证实, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160414/IMG570FBE7A07E895161.jpg, createdBy=681a1704705, createdName=田田7760, createdTime=Sat Mar 26 18:50:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73821, encodeId=1895e3821a4, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Sat Mar 26 06:45:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73803, encodeId=4139e3803e3, content=是这样吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:35:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73804, encodeId=db91e380452, content=要多看文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:35:00 CST 2016, time=2016-03-26, status=1, ipAttribution=)]
    2016-03-26 1ddc978cm67(暂无匿称)

    谢谢分享。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2082370, encodeId=a79020823e0c2, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Apr 24 12:28:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325203, encodeId=5a7f132520345, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 27 10:28:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73884, encodeId=9c0be3884cb, content=需要进一步的研究证实, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160414/IMG570FBE7A07E895161.jpg, createdBy=681a1704705, createdName=田田7760, createdTime=Sat Mar 26 18:50:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73821, encodeId=1895e3821a4, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Sat Mar 26 06:45:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73803, encodeId=4139e3803e3, content=是这样吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:35:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73804, encodeId=db91e380452, content=要多看文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:35:00 CST 2016, time=2016-03-26, status=1, ipAttribution=)]
    2016-03-26 milkshark

    是这样吗

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2082370, encodeId=a79020823e0c2, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Apr 24 12:28:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325203, encodeId=5a7f132520345, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 27 10:28:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73884, encodeId=9c0be3884cb, content=需要进一步的研究证实, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160414/IMG570FBE7A07E895161.jpg, createdBy=681a1704705, createdName=田田7760, createdTime=Sat Mar 26 18:50:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73821, encodeId=1895e3821a4, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Sat Mar 26 06:45:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73803, encodeId=4139e3803e3, content=是这样吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:35:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73804, encodeId=db91e380452, content=要多看文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Mar 26 03:35:00 CST 2016, time=2016-03-26, status=1, ipAttribution=)]
    2016-03-26 milkshark

    要多看文献

    0

相关资讯

Ann Intern Med:乳房大、射片多,增加辐射相关乳腺癌风险

从50岁开始每两年进行一次乳房钼靶检查可降低放射线暴露导致的乳腺癌风险。更大的乳房或隆乳术女性因为辐射的频率和剂量,乳腺癌发病率和死亡率风险更高。该篇发表在内科医学年鉴上的建模研究或会用于更新临床实践建议。重复的数字化乳腺钼靶摄影检查使女性暴露于电离辐射,会增加乳腺癌风险。研究者使用了电脑建模,根据女性筛查频率和剂量的变化,评估数字乳腺X线摄影术中辐射诱发的乳腺癌发生率和死亡率。研究者发现,每年进

Eur Radiol:钼靶乳腺密度低的乳腺癌可能预后不佳

芬兰东部大学最近的一项研究结果指出,非常低的钼靶乳腺密度(MBD)预兆着乳腺癌预后恶化。报道称,钼靶乳腺密度较低的乳腺癌患者,其无病生存期以及总生存期均较钼靶乳腺密度较高的短。乳房组织密度越低,意味着乳房组织内纤维腺体组织比脂肪组织少越多。在未来的临床实践中,这些发现可能为乳腺癌预后的评估和治疗计划的制定提供重要的依据。这项研究涉及了270名乳腺癌患者的研究在Kuopio大学医院进行,入组患者年龄

J Natl Cancer Inst:乳腺癌筛查——超声和钼靶比较

乳腺钼靶检查并没有在全世界范围内广泛应用,但当今乳腺癌发生率不断攀升却是事实。研究者进行了一项研究,拟探究超声对乳腺癌筛查的性能特点。该研究纳入了美国、加拿大、阿根廷等20个低点的2809名参与者,有2662名参与者完成了3年的超声筛查(共7473次检查)、屏幕式钼靶检查(n = 4351) 或数字化钼靶检查(n = 3122)和活检或者随访12个月。研究数据显示,110名女性共发生了111例乳腺

BMJ研究新闻:乳腺癌筛查中超声检查与钼靶X线检查的结果相似

据发表于Journal of the National Cancer Institute的一项新的研究表明,作为乳腺癌一个主要的筛查措施,超声检测与钼靶X线检测的乳腺癌检测率类似。该研究发现,超声检测可更好的检测浸润性且淋巴结阴性的乳腺癌,但是超声检测的假阳性结果也很高。

Lancet:乳腺癌筛查:钼靶+超声 vs 钼靶

目前临床上对乳腺癌筛查认可的检查方式是钼靶摄影,早期筛查可以减少乳腺癌死亡率,不过该方法在临床上对年轻女性或致密乳房的女性是不准确的。研究者进行了一项研究,调查在钼靶基础上,添加辅助超声对乳腺癌筛查的有效性。该研究在2007年7月-2011年3月间、23个地区、42个研究中心,纳入了年龄在40-49岁的无症状女性。参与者在过去5年没有任何癌症病史,且存活5年以上。按1:1将其随机分为钼靶+超声组和

Ann Intern Med:导致乳腺癌钼靶射线假阳性率和假阴性率升高的因素

年轻女性和有乳腺癌风险因素的女性在进行乳腺钼靶检查时常常会出现假阳性结果和需要其他影像学检查,而组织活检使用较少,假阴性筛查率低。美国预防服务工作队发表在内科医学年鉴上的分析或将用于临床实践推荐的更新。临床指南推荐个性化的乳腺钼靶筛查,该方法考虑到乳腺癌的个体危险因素以及筛查潜在的益处和危害。研究人员对405 191名年龄在40岁到89岁的女性数据进行分析,估计钼靶筛查乳腺癌时的假阳性率和假阴性率